SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Menlo Therapeutics, Inc.
(Name of Issuer)
(Title of class of securities)
January 3, 2019
(Date of event which requires filing of this statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The CUSIP number is for the American Depositary Shares that trade on the NASDAQ Global Market, each representing eight ordinary shares. No CUSIP number has been assigned to the Ordinary Shares.
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|CUSIP No. 586858102|
Name of Reporting Person:
Novo Holdings A/S
Check the Appropriate Box if a Member of Group (See Instructions):
(a) ☐ (b) ☐
SEC Use Only:
Citizenship or Place of Organization:
Sole Voting Power:
Shared Voting Power:
Sole Dispositive Power:
Shared Dispositive Power:
Aggregate Amount Beneficially Owned by Each Reporting Person:
Check if the Aggregate Amount in Row (9) Excludes Certain Shares: ☐
Percent of Class Represented By Amount In Row (9):
Type of Reporting Person:
This Amendment No. 1 amends the Schedule 13G originally filed with the Securities and Exchange Commission (the SEC) on February 2, 2018. Except as specifically amended by this Amendment No. 1, each Item of the amended statement remains unchanged. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule. As of January 3, 2019, the Reporting Person ceased to be the beneficial owner of more than five percent of the Issuers securities reported herein.
|Item 1.|| |
(a) Name of Issuer:
Menlo Pharmaceuticals, Inc.
(b) Address of Issuers Principal Executive Offices:
200 Cardinal Way, 2nd Floor
Redwood City, CA 94063
|Item 2.|| |
(a) Name of Person Filing:
Novo Holdings A/S, a Danish limited liability company, is wholly owned by Novo Nordisk Fonden (the Foundation), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S, Novozymes A/S and NNIT A/S) and is responsible for managing the Foundations assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.
(b) Address or Principal Business Office or, if none, Residence:
Tuborg Havnevej 19
2900 Hellerup, Denmark
(c) Citizenship or Place of Organization:
Novo Holdings A/S: Denmark
(d) Title of Class of Securities:
(e) CUSIP Number:
|Item 3.|| |
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
|Item 4.|| |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
Amount beneficially owned:
Percent of class:
Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote:
(ii) Shared power to vote or to direct the vote:
(iii) Sole power to dispose or to direct the disposition of:
(iv) Shared power to dispose or to direct the disposition of:
|Item 5.|| |
Ownership of Five Percent or Less of a Class:
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class or securities, check the following ☒.
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|Dated: January 7, 2019||Novo Holdings A/S|
|/s/ Peter Haahr|
|By: Peter Haahr|
|Its: Chief Financial Officer|